Your session is about to expire
← Back to Search
Loncastuximab Tesirine for Non-Hodgkin's Lymphoma
Study Summary
This trial will test if a new drug, loncastuximab tesirine, can help control large B-cell lymphoma that has returned or is resistant to CAR T-cell therapy. The safety and possible effects of the new drug will also be studied.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an autoimmune disease that has damaged my organs or needed strong medication in the last 2 years.I have fluid buildup needing drainage or causing breathing issues.I am currently pregnant or breastfeeding.I do not have any severe infections requiring strong antibiotics or antifungals.My white blood cell count is healthy without needing medication for the last 3 days.I am receiving an FDA-approved CAR T-cell therapy for my condition.I am capable of becoming pregnant and have a negative pregnancy test.I received CAR T-cell therapy as my last treatment before joining this study.I haven't had a heart attack or other major heart issues in the last year.I am 18 years old or older.I am not willing to use birth control.My cancer responded well to CAR T-cell therapy within 30 days.I haven't had cancer treatment after my CAR T-cell therapy, except for palliative radiotherapy.It has been over 30 days since my last CAR T-cell therapy infusion.My lymphoma has not spread to my brain or spinal cord.My heart pumps well and I don't have serious fluid around it.I haven't had serious blood clots or lung blockages in the last month.I am able to care for myself and perform daily activities.I have HIV, hepatitis B, or C but my viral load is undetectable.I do not have any health issues that could affect the study's results.My CLL has transformed into a more aggressive form.I have previously been treated with lonca.My condition is a type of aggressive B-cell lymphoma that has returned or didn't respond to treatment.I had no lasting effects from previous immune-related side effects.My kidneys are functioning well enough (creatinine clearance over 30 mL/min).My heart is affected by lymphoma.I have been cancer-free for at least a year, except for nonmelanoma skin cancer or carcinoma in situ.
- Group 1: Loncastuximab Tesirine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the dangers associated with Loncastuximab Tesirine?
"While Phase 2 trials offer preliminary evidence regarding a medication's safety, there is no data yet supporting efficacy. Therefore, our team at Power has rated the Loncastuximab Tesirine as a 2."
What is the total number of participants for this clinical trial?
"That is right, the clinicaltrials.gov website has information indicating that this study is looking for subjects. This research was originally put up on September 23rd, 2022 and was updated recently on the same day. The study needs 30 individuals from 1 location."
Are there any available positions for participants in this trial?
"Yes, this study is looking for participants and the most recent update was on September 23rd, 2022."
Share this study with friends
Copy Link
Messenger